Inhaled molecule aims to halt lung scarring in first human tests
NCT ID NCT06589219
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This early-stage trial tests an inhaled drug called CMR316 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. The study's main goal is to check the drug's safety and how the body processes it. Participants receive either CMR316 or a placebo via a nebulizer. If the drug proves safe, it could lead to a new way to treat IPF.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CMR316 (nebulized)
- What this could lead to
- If safe and effective, CMR316 could offer a new inhaled treatment option for idiopathic pulmonary fibrosis, a serious lung-scarring disease.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not yet on efficacy. The drug may cause side effects or fail to improve lung function in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSES, IDIOPATHIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fraunhofer Institute for Toxicology and Experimental Medicine ITEM
Hanover, 30625, Germany